SCHEMBL4878754

SCHEMBL4878754

c1cnc(Nc2cccc(OCCN3CCSCC3)c2)nc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AIMP2 Q13155 2/20 0.54
SRC P12931 5/20 0.47
YES1 P07947 1/20 0.47
PDGFRB P09619 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
LMNA P02545 1/20 0.46
MAPK1 P28482 1/20 0.46
HTT P42858 1/20 0.46
EPHX2 P34913 3/20 0.44
SYK P43405 2/20 0.44
CHRNB2 P17787 1/20 0.44
CHRNA4 P43681 1/20 0.44
EGFR P00533 2/20 0.44
ABL1 P00519 1/20 0.44
BCR P11274 1/20 0.44
PRKCA P17252 1/20 0.44
PRKCD Q05655 1/20 0.44
LTA4H P09960 1/20 0.43
BTK Q06187 1/20 0.42
PIK3CA P42336 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3458886 0.94 EPHX2 (0.51) AIMP2SRCPDGFRBEPHX2EGFR
SCHEMBL4880015 0.89 AIMP2 (0.57) AIMP2SRCYES1PDGFRBSMN1; SMN2
SCHEMBL3459344 0.85 SRC (0.59) AIMP2SRCHTTEPHX2SYK
SCHEMBL3459641 0.82 AIMP2 (0.50) AIMP2SRCYES1PDGFRBEPHX2
SCHEMBL3458627 0.80 EPHX2 (0.64) HTTEPHX2EGFRKDM4EALDH1A1
SCHEMBL14024416 0.78 AIMP2 (0.48) AIMP2SRCYES1SYKEGFR
SCHEMBL13924567 0.78 SYK (0.62) AIMP2SRCSYKEGFRABL1
SCHEMBL12190209 0.77 SRC (0.56) AIMP2SRCYES1PDGFRBSMN1; SMN2
SCHEMBL3458766 0.77 AIMP2 (0.58) AIMP2SRCYES1PDGFRBSMN1; SMN2
SCHEMBL14024533 0.77 KDR (0.54) AIMP2SRCYES1PDGFRBSYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8349859-B2 Pyrimidine derivatives HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) 2013-01-08 US disclosed
US-20080255172-A1 N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration HUTCHISON MEDIPHARMA ENTERPRISES LIMETED (BS) 2008-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255172-A1 N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration CCND2, KDR, FLT4 AIMP2 439/4885SRC 4249/4885YES1 1038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.